Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Freudenberger

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Journal of the American College of Cardiology|February 16, 2018
Risk Scores-Medical DerivativesRonald S Freudenberger
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and riskR S Freudenberger, V Fuster
Transplantation Proceedings|June 27, 2006
Cutaneous infection with rapidly-growing mycobacterial infection following heart transplant: a case report and review of the literatureR S Freudenberger, S M Simafranca
The Annals of Pharmacotherapy|January 27, 2004
Ephedra-associated cardiomyopathySarjita D Naik, Ronald S Freudenberger
Current Heart Failure Reports|May 25, 2007
Beta-blocker contraindications: are there patients or situations where use is inappropriate?S D Naik, Ronald S Freudenberger
Current Opinion in Critical Care|September 26, 2003
Is there an optimal hemoglobin value in the cardiac intensive care unit?Ronald S Freudenberger, Jeffrey L Carson
Journal of Cardiac Failure|October 4, 2005
Silent cerebral infarction in heart failure: vascular or thromboembolic?Ronald S Freudenberger, Barry M Massie
Nature Clinical Practice. Cardiovascular Medicine|October 26, 2006
Should we use anticoagulation for patients with chronic heart failure?Ronald S Freudenberger, Jonathan L Halperin
Current Opinion in Cardiology|April 3, 2008
What do we know about anticoagulation in patients with heart failure?Amy M Ahnert, Ronald S Freudenberger
Antimicrobial Agents and Chemotherapy|September 1, 1982
Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteriaK Bush, J S Freudenberger, R B Sykes
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Journal of the American College of Cardiology|February 16, 2018
Risk Scores-Medical DerivativesRonald S Freudenberger
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and riskR S Freudenberger, V Fuster
Transplantation Proceedings|June 27, 2006
Cutaneous infection with rapidly-growing mycobacterial infection following heart transplant: a case report and review of the literatureR S Freudenberger, S M Simafranca
The Annals of Pharmacotherapy|January 27, 2004
Ephedra-associated cardiomyopathySarjita D Naik, Ronald S Freudenberger
Current Heart Failure Reports|May 25, 2007
Beta-blocker contraindications: are there patients or situations where use is inappropriate?S D Naik, Ronald S Freudenberger
Current Opinion in Critical Care|September 26, 2003
Is there an optimal hemoglobin value in the cardiac intensive care unit?Ronald S Freudenberger, Jeffrey L Carson
Journal of Cardiac Failure|October 4, 2005
Silent cerebral infarction in heart failure: vascular or thromboembolic?Ronald S Freudenberger, Barry M Massie
Nature Clinical Practice. Cardiovascular Medicine|October 26, 2006
Should we use anticoagulation for patients with chronic heart failure?Ronald S Freudenberger, Jonathan L Halperin
Current Opinion in Cardiology|April 3, 2008
What do we know about anticoagulation in patients with heart failure?Amy M Ahnert, Ronald S Freudenberger
Antimicrobial Agents and Chemotherapy|September 1, 1982
Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteriaK Bush, J S Freudenberger, R B Sykes
Pageof 6